Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The CLI-05993AA5-06 study is an interventional study designed to investigate the safety and efficacy of a new experimental drug called CHF5993 pMDI compared to the currently approved Seretide 125 Evohaler pMDI in adolescent patients with uncontrolled asthma.
Epistemonikos ID: 2629c843178ae23ac0b980a2e05d4d44606a01b0
First added on: Oct 06, 2026